Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria
Cystic echinococcosis (CE) is a globally occurring zoonosis, whereas alveolar echinococcosis (AE) is endemic only in certain parts of the Northern Hemisphere. The socioeconomic impact of human echinococcosis has been shown to be considerable in highly endemic regions. However, detailed data on direc...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2019-01, Vol.13 (1), p.e0007110-e0007110 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0007110 |
|---|---|
| container_issue | 1 |
| container_start_page | e0007110 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 13 |
| creator | Lötsch, Felix Budke, Christine M Auer, Herbert Kaczirek, Klaus Waneck, Fredrik Lagler, Heimo Ramharter, Michael |
| description | Cystic echinococcosis (CE) is a globally occurring zoonosis, whereas alveolar echinococcosis (AE) is endemic only in certain parts of the Northern Hemisphere. The socioeconomic impact of human echinococcosis has been shown to be considerable in highly endemic regions. However, detailed data on direct healthcare-related costs associated with CE and AE are scarce for high income countries. The aim of this study was to evaluate direct costs of human disease caused by CE and AE in Austria.
Clinical data from a registry maintained at a national reference center for echinococcosis at the Medical University of Vienna were obtained for the years 2012-2014. These data were used in conjunction with epidemiological data from Austria's national disease reporting system and diagnostic reference laboratory for echinococcosis to assess nationwide costs attributable to CE and AE.
In Austria, total modelled direct costs were 486,598€ (95%CI 341,825€ - 631,372€) per year for CE, and 683,824€ (95%CI 469,161€ - 898,486€) for AE. Median costs per patient with AE from diagnosis until the end of a 10-year follow-up period were 30,832€ (25th- 75th percentile: 23,197€ - 31,220€) and 62,777€ (25th- 75th percentile: 60,806€ - 67,867€) for inoperable and operable patients, respectively. Median costs per patients with CE from diagnosis until end of follow-up after 10 years were 16,253€ (25th- 75th percentile: 8,555€ - 24,832€) and 1,786€ (25th- 75th percentile: 736€ - 2,146€) for patients with active and inactive cyst stages, respectively. The first year after inclusion was the most cost-intense year in the observed period, with hospitalizations and albendazole therapy the main contributors to direct costs.
This study provides detailed information on direct healthcare-related costs associated with CE and AE in Austria, which may reflect trends for other high-income countries. Surgery and albendazole therapy, due to surprisingly high drug prices, were identified as important cost-drivers. These data will be important for cost-effectiveness analyses of possible prevention programs. |
| doi_str_mv | 10.1371/journal.pntd.0007110 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2262859879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A571883853</galeid><doaj_id>oai_doaj_org_article_4f443f8b3c094656bb83bc56bdf951d4</doaj_id><sourcerecordid>A571883853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-f600354a4551eecd1ef6fae1b961c8eb1c6125418d73f6a8e59cf4d3a736d74d3</originalsourceid><addsrcrecordid>eNptUluLEzEYHURxL_oPRAcE8aU1mVznZaEsqy4s-KLgW8jk0qakSU0ylf33ptvZpZUlD9_Hl3POd-E0zTsI5hAx-GUdxxSkn29D0XMAAIMQvGjOYY_IrGOIvDzKz5qLnNcAkJ5w-Lo5Q4ABBHp43vy-2Uk_yuJiaKNttUtGlVbFXHIrc47KyWJ0-9eVVSv9zkQvUyuDbtV9Lk61Rq1ciCqqSnG5daFdjLkkJ980r6z02byd4mXz6-vNz-vvs7sf326vF3czRTtcZpYCgAiWmBBojNLQWGqlgUNPoeJmgIrCjmDINUOWSm5IryzWSDJENavJZfPhoLv1MYvpKFl0He046TnrK-L2gNBRrsU2uY1M9yJKJx4KMS2FTHUXbwS2GCPLB6RAjymhw8DRoGrUtidQ46p1NXUbh43RyoSSpD8RPf0JbiWWcSdoXbKnqAp8ngRS_DOaXMTGZWW8l8HEsc4NWY8544xV6Mf_oM9vN6GWsi7ggo21r9qLigVhkHPEyb7t_BlUfdpsnIrBWFfrJ4RPR4SVkb6scvTj3ij5FIgPQJVizsnYp2NAIPZGfZxa7I0qJqNW2vvjQz6RHp2J_gGDU-WJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2262859879</pqid></control><display><type>article</type><title>Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lötsch, Felix ; Budke, Christine M ; Auer, Herbert ; Kaczirek, Klaus ; Waneck, Fredrik ; Lagler, Heimo ; Ramharter, Michael</creator><contributor>Siles-Lucas, Mar</contributor><creatorcontrib>Lötsch, Felix ; Budke, Christine M ; Auer, Herbert ; Kaczirek, Klaus ; Waneck, Fredrik ; Lagler, Heimo ; Ramharter, Michael ; Siles-Lucas, Mar</creatorcontrib><description>Cystic echinococcosis (CE) is a globally occurring zoonosis, whereas alveolar echinococcosis (AE) is endemic only in certain parts of the Northern Hemisphere. The socioeconomic impact of human echinococcosis has been shown to be considerable in highly endemic regions. However, detailed data on direct healthcare-related costs associated with CE and AE are scarce for high income countries. The aim of this study was to evaluate direct costs of human disease caused by CE and AE in Austria.
Clinical data from a registry maintained at a national reference center for echinococcosis at the Medical University of Vienna were obtained for the years 2012-2014. These data were used in conjunction with epidemiological data from Austria's national disease reporting system and diagnostic reference laboratory for echinococcosis to assess nationwide costs attributable to CE and AE.
In Austria, total modelled direct costs were 486,598€ (95%CI 341,825€ - 631,372€) per year for CE, and 683,824€ (95%CI 469,161€ - 898,486€) for AE. Median costs per patient with AE from diagnosis until the end of a 10-year follow-up period were 30,832€ (25th- 75th percentile: 23,197€ - 31,220€) and 62,777€ (25th- 75th percentile: 60,806€ - 67,867€) for inoperable and operable patients, respectively. Median costs per patients with CE from diagnosis until end of follow-up after 10 years were 16,253€ (25th- 75th percentile: 8,555€ - 24,832€) and 1,786€ (25th- 75th percentile: 736€ - 2,146€) for patients with active and inactive cyst stages, respectively. The first year after inclusion was the most cost-intense year in the observed period, with hospitalizations and albendazole therapy the main contributors to direct costs.
This study provides detailed information on direct healthcare-related costs associated with CE and AE in Austria, which may reflect trends for other high-income countries. Surgery and albendazole therapy, due to surprisingly high drug prices, were identified as important cost-drivers. These data will be important for cost-effectiveness analyses of possible prevention programs.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0007110</identifier><identifier>PMID: 30703091</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Albendazole ; Alveoli ; Analysis ; Austria ; Care and treatment ; Child ; Cost analysis ; Cost assessments ; Cost benefit analysis ; Cost estimates ; Costs ; Countries ; Cysts ; Data ; Developed Countries ; Diagnosis ; Diagnostic systems ; Drug dosages ; Echinococcosis ; Echinococcosis - drug therapy ; Echinococcosis - economics ; Echinococcosis - surgery ; Economic aspects ; Economic impact ; Epidemiology ; Female ; Health care ; Health Care Costs ; Hospitalization ; Hospitals ; Human diseases ; Humans ; Income ; Infectious diseases ; Internet ; Laboratories ; Macrophages ; Male ; Medical economics ; Medical imaging ; Medical schools ; Medicine and Health Sciences ; Middle Aged ; NMR ; Northern Hemisphere ; Nuclear magnetic resonance ; Parasitology ; Patients ; People and places ; Prescription drugs ; Research and Analysis Methods ; Social aspects ; Social Sciences ; Surgery ; Therapy ; Tomography ; Tropical diseases ; Universities and colleges ; Veterinary medicine ; Young Adult ; Zoonoses</subject><ispartof>PLoS neglected tropical diseases, 2019-01, Vol.13 (1), p.e0007110-e0007110</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Lötsch et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Lötsch et al 2019 Lötsch et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-f600354a4551eecd1ef6fae1b961c8eb1c6125418d73f6a8e59cf4d3a736d74d3</citedby><cites>FETCH-LOGICAL-c624t-f600354a4551eecd1ef6fae1b961c8eb1c6125418d73f6a8e59cf4d3a736d74d3</cites><orcidid>0000-0002-6938-9523 ; 0000-0002-9259-1885 ; 0000-0002-4750-0905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354963/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354963/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30703091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Siles-Lucas, Mar</contributor><creatorcontrib>Lötsch, Felix</creatorcontrib><creatorcontrib>Budke, Christine M</creatorcontrib><creatorcontrib>Auer, Herbert</creatorcontrib><creatorcontrib>Kaczirek, Klaus</creatorcontrib><creatorcontrib>Waneck, Fredrik</creatorcontrib><creatorcontrib>Lagler, Heimo</creatorcontrib><creatorcontrib>Ramharter, Michael</creatorcontrib><title>Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>Cystic echinococcosis (CE) is a globally occurring zoonosis, whereas alveolar echinococcosis (AE) is endemic only in certain parts of the Northern Hemisphere. The socioeconomic impact of human echinococcosis has been shown to be considerable in highly endemic regions. However, detailed data on direct healthcare-related costs associated with CE and AE are scarce for high income countries. The aim of this study was to evaluate direct costs of human disease caused by CE and AE in Austria.
Clinical data from a registry maintained at a national reference center for echinococcosis at the Medical University of Vienna were obtained for the years 2012-2014. These data were used in conjunction with epidemiological data from Austria's national disease reporting system and diagnostic reference laboratory for echinococcosis to assess nationwide costs attributable to CE and AE.
In Austria, total modelled direct costs were 486,598€ (95%CI 341,825€ - 631,372€) per year for CE, and 683,824€ (95%CI 469,161€ - 898,486€) for AE. Median costs per patient with AE from diagnosis until the end of a 10-year follow-up period were 30,832€ (25th- 75th percentile: 23,197€ - 31,220€) and 62,777€ (25th- 75th percentile: 60,806€ - 67,867€) for inoperable and operable patients, respectively. Median costs per patients with CE from diagnosis until end of follow-up after 10 years were 16,253€ (25th- 75th percentile: 8,555€ - 24,832€) and 1,786€ (25th- 75th percentile: 736€ - 2,146€) for patients with active and inactive cyst stages, respectively. The first year after inclusion was the most cost-intense year in the observed period, with hospitalizations and albendazole therapy the main contributors to direct costs.
This study provides detailed information on direct healthcare-related costs associated with CE and AE in Austria, which may reflect trends for other high-income countries. Surgery and albendazole therapy, due to surprisingly high drug prices, were identified as important cost-drivers. These data will be important for cost-effectiveness analyses of possible prevention programs.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Albendazole</subject><subject>Alveoli</subject><subject>Analysis</subject><subject>Austria</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Cost analysis</subject><subject>Cost assessments</subject><subject>Cost benefit analysis</subject><subject>Cost estimates</subject><subject>Costs</subject><subject>Countries</subject><subject>Cysts</subject><subject>Data</subject><subject>Developed Countries</subject><subject>Diagnosis</subject><subject>Diagnostic systems</subject><subject>Drug dosages</subject><subject>Echinococcosis</subject><subject>Echinococcosis - drug therapy</subject><subject>Echinococcosis - economics</subject><subject>Echinococcosis - surgery</subject><subject>Economic aspects</subject><subject>Economic impact</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Health care</subject><subject>Health Care Costs</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Human diseases</subject><subject>Humans</subject><subject>Income</subject><subject>Infectious diseases</subject><subject>Internet</subject><subject>Laboratories</subject><subject>Macrophages</subject><subject>Male</subject><subject>Medical economics</subject><subject>Medical imaging</subject><subject>Medical schools</subject><subject>Medicine and Health Sciences</subject><subject>Middle Aged</subject><subject>NMR</subject><subject>Northern Hemisphere</subject><subject>Nuclear magnetic resonance</subject><subject>Parasitology</subject><subject>Patients</subject><subject>People and places</subject><subject>Prescription drugs</subject><subject>Research and Analysis Methods</subject><subject>Social aspects</subject><subject>Social Sciences</subject><subject>Surgery</subject><subject>Therapy</subject><subject>Tomography</subject><subject>Tropical diseases</subject><subject>Universities and colleges</subject><subject>Veterinary medicine</subject><subject>Young Adult</subject><subject>Zoonoses</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNptUluLEzEYHURxL_oPRAcE8aU1mVznZaEsqy4s-KLgW8jk0qakSU0ylf33ptvZpZUlD9_Hl3POd-E0zTsI5hAx-GUdxxSkn29D0XMAAIMQvGjOYY_IrGOIvDzKz5qLnNcAkJ5w-Lo5Q4ABBHp43vy-2Uk_yuJiaKNttUtGlVbFXHIrc47KyWJ0-9eVVSv9zkQvUyuDbtV9Lk61Rq1ciCqqSnG5daFdjLkkJ980r6z02byd4mXz6-vNz-vvs7sf326vF3czRTtcZpYCgAiWmBBojNLQWGqlgUNPoeJmgIrCjmDINUOWSm5IryzWSDJENavJZfPhoLv1MYvpKFl0He046TnrK-L2gNBRrsU2uY1M9yJKJx4KMS2FTHUXbwS2GCPLB6RAjymhw8DRoGrUtidQ46p1NXUbh43RyoSSpD8RPf0JbiWWcSdoXbKnqAp8ngRS_DOaXMTGZWW8l8HEsc4NWY8544xV6Mf_oM9vN6GWsi7ggo21r9qLigVhkHPEyb7t_BlUfdpsnIrBWFfrJ4RPR4SVkb6scvTj3ij5FIgPQJVizsnYp2NAIPZGfZxa7I0qJqNW2vvjQz6RHp2J_gGDU-WJ</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Lötsch, Felix</creator><creator>Budke, Christine M</creator><creator>Auer, Herbert</creator><creator>Kaczirek, Klaus</creator><creator>Waneck, Fredrik</creator><creator>Lagler, Heimo</creator><creator>Ramharter, Michael</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6938-9523</orcidid><orcidid>https://orcid.org/0000-0002-9259-1885</orcidid><orcidid>https://orcid.org/0000-0002-4750-0905</orcidid></search><sort><creationdate>20190101</creationdate><title>Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria</title><author>Lötsch, Felix ; Budke, Christine M ; Auer, Herbert ; Kaczirek, Klaus ; Waneck, Fredrik ; Lagler, Heimo ; Ramharter, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-f600354a4551eecd1ef6fae1b961c8eb1c6125418d73f6a8e59cf4d3a736d74d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Albendazole</topic><topic>Alveoli</topic><topic>Analysis</topic><topic>Austria</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Cost analysis</topic><topic>Cost assessments</topic><topic>Cost benefit analysis</topic><topic>Cost estimates</topic><topic>Costs</topic><topic>Countries</topic><topic>Cysts</topic><topic>Data</topic><topic>Developed Countries</topic><topic>Diagnosis</topic><topic>Diagnostic systems</topic><topic>Drug dosages</topic><topic>Echinococcosis</topic><topic>Echinococcosis - drug therapy</topic><topic>Echinococcosis - economics</topic><topic>Echinococcosis - surgery</topic><topic>Economic aspects</topic><topic>Economic impact</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Health care</topic><topic>Health Care Costs</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Human diseases</topic><topic>Humans</topic><topic>Income</topic><topic>Infectious diseases</topic><topic>Internet</topic><topic>Laboratories</topic><topic>Macrophages</topic><topic>Male</topic><topic>Medical economics</topic><topic>Medical imaging</topic><topic>Medical schools</topic><topic>Medicine and Health Sciences</topic><topic>Middle Aged</topic><topic>NMR</topic><topic>Northern Hemisphere</topic><topic>Nuclear magnetic resonance</topic><topic>Parasitology</topic><topic>Patients</topic><topic>People and places</topic><topic>Prescription drugs</topic><topic>Research and Analysis Methods</topic><topic>Social aspects</topic><topic>Social Sciences</topic><topic>Surgery</topic><topic>Therapy</topic><topic>Tomography</topic><topic>Tropical diseases</topic><topic>Universities and colleges</topic><topic>Veterinary medicine</topic><topic>Young Adult</topic><topic>Zoonoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lötsch, Felix</creatorcontrib><creatorcontrib>Budke, Christine M</creatorcontrib><creatorcontrib>Auer, Herbert</creatorcontrib><creatorcontrib>Kaczirek, Klaus</creatorcontrib><creatorcontrib>Waneck, Fredrik</creatorcontrib><creatorcontrib>Lagler, Heimo</creatorcontrib><creatorcontrib>Ramharter, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lötsch, Felix</au><au>Budke, Christine M</au><au>Auer, Herbert</au><au>Kaczirek, Klaus</au><au>Waneck, Fredrik</au><au>Lagler, Heimo</au><au>Ramharter, Michael</au><au>Siles-Lucas, Mar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>13</volume><issue>1</issue><spage>e0007110</spage><epage>e0007110</epage><pages>e0007110-e0007110</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>Cystic echinococcosis (CE) is a globally occurring zoonosis, whereas alveolar echinococcosis (AE) is endemic only in certain parts of the Northern Hemisphere. The socioeconomic impact of human echinococcosis has been shown to be considerable in highly endemic regions. However, detailed data on direct healthcare-related costs associated with CE and AE are scarce for high income countries. The aim of this study was to evaluate direct costs of human disease caused by CE and AE in Austria.
Clinical data from a registry maintained at a national reference center for echinococcosis at the Medical University of Vienna were obtained for the years 2012-2014. These data were used in conjunction with epidemiological data from Austria's national disease reporting system and diagnostic reference laboratory for echinococcosis to assess nationwide costs attributable to CE and AE.
In Austria, total modelled direct costs were 486,598€ (95%CI 341,825€ - 631,372€) per year for CE, and 683,824€ (95%CI 469,161€ - 898,486€) for AE. Median costs per patient with AE from diagnosis until the end of a 10-year follow-up period were 30,832€ (25th- 75th percentile: 23,197€ - 31,220€) and 62,777€ (25th- 75th percentile: 60,806€ - 67,867€) for inoperable and operable patients, respectively. Median costs per patients with CE from diagnosis until end of follow-up after 10 years were 16,253€ (25th- 75th percentile: 8,555€ - 24,832€) and 1,786€ (25th- 75th percentile: 736€ - 2,146€) for patients with active and inactive cyst stages, respectively. The first year after inclusion was the most cost-intense year in the observed period, with hospitalizations and albendazole therapy the main contributors to direct costs.
This study provides detailed information on direct healthcare-related costs associated with CE and AE in Austria, which may reflect trends for other high-income countries. Surgery and albendazole therapy, due to surprisingly high drug prices, were identified as important cost-drivers. These data will be important for cost-effectiveness analyses of possible prevention programs.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30703091</pmid><doi>10.1371/journal.pntd.0007110</doi><orcidid>https://orcid.org/0000-0002-6938-9523</orcidid><orcidid>https://orcid.org/0000-0002-9259-1885</orcidid><orcidid>https://orcid.org/0000-0002-4750-0905</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2019-01, Vol.13 (1), p.e0007110-e0007110 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_2262859879 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Aged Aged, 80 and over Albendazole Alveoli Analysis Austria Care and treatment Child Cost analysis Cost assessments Cost benefit analysis Cost estimates Costs Countries Cysts Data Developed Countries Diagnosis Diagnostic systems Drug dosages Echinococcosis Echinococcosis - drug therapy Echinococcosis - economics Echinococcosis - surgery Economic aspects Economic impact Epidemiology Female Health care Health Care Costs Hospitalization Hospitals Human diseases Humans Income Infectious diseases Internet Laboratories Macrophages Male Medical economics Medical imaging Medical schools Medicine and Health Sciences Middle Aged NMR Northern Hemisphere Nuclear magnetic resonance Parasitology Patients People and places Prescription drugs Research and Analysis Methods Social aspects Social Sciences Surgery Therapy Tomography Tropical diseases Universities and colleges Veterinary medicine Young Adult Zoonoses |
| title | Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20direct%20costs%20associated%20with%20alveolar%20and%20cystic%20echinococcosis%20in%20Austria&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=L%C3%B6tsch,%20Felix&rft.date=2019-01-01&rft.volume=13&rft.issue=1&rft.spage=e0007110&rft.epage=e0007110&rft.pages=e0007110-e0007110&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0007110&rft_dat=%3Cgale_plos_%3EA571883853%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2262859879&rft_id=info:pmid/30703091&rft_galeid=A571883853&rft_doaj_id=oai_doaj_org_article_4f443f8b3c094656bb83bc56bdf951d4&rfr_iscdi=true |